WO2022137638A1 - 水中油型乳化化粧料 - Google Patents
水中油型乳化化粧料 Download PDFInfo
- Publication number
- WO2022137638A1 WO2022137638A1 PCT/JP2021/029917 JP2021029917W WO2022137638A1 WO 2022137638 A1 WO2022137638 A1 WO 2022137638A1 JP 2021029917 W JP2021029917 W JP 2021029917W WO 2022137638 A1 WO2022137638 A1 WO 2022137638A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oil
- acid
- vesicle
- group
- poe
- Prior art date
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 96
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 41
- 239000000126 substance Substances 0.000 claims abstract description 29
- 239000000049 pigment Substances 0.000 claims abstract description 28
- 239000006097 ultraviolet radiation absorber Substances 0.000 claims abstract description 21
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 claims abstract description 19
- 229960001679 octinoxate Drugs 0.000 claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 49
- 229920001296 polysiloxane Polymers 0.000 claims description 44
- 150000001413 amino acids Chemical class 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 239000003945 anionic surfactant Substances 0.000 claims description 16
- 150000001298 alcohols Chemical class 0.000 claims description 11
- 239000002563 ionic surfactant Substances 0.000 claims description 11
- 230000002087 whitening effect Effects 0.000 claims description 9
- 150000003872 salicylic acid derivatives Chemical class 0.000 claims description 3
- 238000002156 mixing Methods 0.000 abstract description 47
- 230000000694 effects Effects 0.000 abstract description 21
- 239000011248 coating agent Substances 0.000 abstract description 12
- 238000000576 coating method Methods 0.000 abstract description 12
- 230000035807 sensation Effects 0.000 abstract description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- -1 polyoxyethylene Polymers 0.000 description 92
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 84
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 66
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 55
- 239000003921 oil Substances 0.000 description 53
- 235000019198 oils Nutrition 0.000 description 49
- 235000019441 ethanol Nutrition 0.000 description 46
- 229940024606 amino acid Drugs 0.000 description 42
- 235000001014 amino acid Nutrition 0.000 description 42
- 239000008346 aqueous phase Substances 0.000 description 31
- 150000002009 diols Chemical class 0.000 description 27
- 238000004945 emulsification Methods 0.000 description 27
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 24
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 21
- 239000002107 nanodisc Substances 0.000 description 21
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 19
- 125000002947 alkylene group Chemical group 0.000 description 19
- 150000003839 salts Chemical class 0.000 description 19
- 125000004432 carbon atom Chemical group C* 0.000 description 18
- 239000012071 phase Substances 0.000 description 18
- 239000002253 acid Substances 0.000 description 17
- 235000014113 dietary fatty acids Nutrition 0.000 description 17
- 239000000194 fatty acid Substances 0.000 description 17
- 229930195729 fatty acid Natural products 0.000 description 17
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 16
- ATFFFUXLAJBBDE-FQEVSTJZSA-N N-Stearoyl glutamic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCC(O)=O ATFFFUXLAJBBDE-FQEVSTJZSA-N 0.000 description 16
- 229940072873 stearoyl glutamic acid Drugs 0.000 description 16
- 238000003756 stirring Methods 0.000 description 15
- 239000004205 dimethyl polysiloxane Substances 0.000 description 13
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 13
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 13
- 239000002211 L-ascorbic acid Substances 0.000 description 12
- 229960005070 ascorbic acid Drugs 0.000 description 12
- 235000013980 iron oxide Nutrition 0.000 description 12
- 239000000539 dimer Substances 0.000 description 11
- 239000006185 dispersion Substances 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- NUHMQHLCUWSBCS-UHFFFAOYSA-N 10-(16-methylheptadecoxy)-10-oxodecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCC(O)=O NUHMQHLCUWSBCS-UHFFFAOYSA-N 0.000 description 10
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 235000000069 L-ascorbic acid Nutrition 0.000 description 10
- 239000004359 castor oil Substances 0.000 description 10
- 235000019438 castor oil Nutrition 0.000 description 10
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000004094 surface-active agent Substances 0.000 description 10
- 230000001804 emulsifying effect Effects 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 150000004665 fatty acids Chemical class 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 8
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 8
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 8
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 8
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 8
- 125000006353 oxyethylene group Chemical group 0.000 description 8
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 8
- 229940008099 dimethicone Drugs 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 7
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000003012 bilayer membrane Substances 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 6
- 125000005702 oxyalkylene group Chemical group 0.000 description 6
- 229960000401 tranexamic acid Drugs 0.000 description 6
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 6
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 6
- 125000004442 acylamino group Chemical group 0.000 description 5
- 238000005054 agglomeration Methods 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical class NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 5
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 4
- KZRXPHCVIMWWDS-AWEZNQCLSA-N (4S)-4-amino-5-dodecanoyloxy-5-oxopentanoic acid Chemical compound CCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCC(O)=O KZRXPHCVIMWWDS-AWEZNQCLSA-N 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 4
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 230000006750 UV protection Effects 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 4
- 239000001685 glycyrrhizic acid Substances 0.000 description 4
- 229960004949 glycyrrhizic acid Drugs 0.000 description 4
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 4
- 235000019410 glycyrrhizin Nutrition 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 229960004881 homosalate Drugs 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 229940071085 lauroyl glutamate Drugs 0.000 description 4
- 239000004973 liquid crystal related substance Substances 0.000 description 4
- POPACFLNWGUDSR-UHFFFAOYSA-N methoxy(trimethyl)silane Chemical compound CO[Si](C)(C)C POPACFLNWGUDSR-UHFFFAOYSA-N 0.000 description 4
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 4
- 229960000601 octocrylene Drugs 0.000 description 4
- 150000004671 saturated fatty acids Chemical class 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 150000005846 sugar alcohols Polymers 0.000 description 4
- 239000010936 titanium Substances 0.000 description 4
- 229910052719 titanium Inorganic materials 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- IZZIWIAOVZOBLF-UHFFFAOYSA-N 5-methyloxysalicylic acid Natural products COC1=CC=C(O)C(C(O)=O)=C1 IZZIWIAOVZOBLF-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 239000006096 absorbing agent Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000005690 diesters Chemical class 0.000 description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 3
- 229940068171 ethyl hexyl salicylate Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 229940082006 potassium cocoyl glutamate Drugs 0.000 description 3
- RMGVATURDVPNOZ-UHFFFAOYSA-M potassium;hexadecyl hydrogen phosphate Chemical compound [K+].CCCCCCCCCCCCCCCCOP(O)([O-])=O RMGVATURDVPNOZ-UHFFFAOYSA-M 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000004381 surface treatment Methods 0.000 description 3
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 2
- YWWVWXASSLXJHU-AATRIKPKSA-N (9E)-tetradecenoic acid Chemical compound CCCC\C=C\CCCCCCCC(O)=O YWWVWXASSLXJHU-AATRIKPKSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- XHZPRMZZQOIPDS-UHFFFAOYSA-N 2-Methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)NC(=O)C=C XHZPRMZZQOIPDS-UHFFFAOYSA-N 0.000 description 2
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 description 2
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- GTJOHISYCKPIMT-UHFFFAOYSA-N 2-methylundecane Chemical compound CCCCCCCCCC(C)C GTJOHISYCKPIMT-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- AUZQQIPZESHNMG-UHFFFAOYSA-N 3-methoxysalicylic acid Chemical compound COC1=CC=CC(C(O)=O)=C1O AUZQQIPZESHNMG-UHFFFAOYSA-N 0.000 description 2
- WHNPOQXWAMXPTA-UHFFFAOYSA-N 3-methylbut-2-enamide Chemical compound CC(C)=CC(N)=O WHNPOQXWAMXPTA-UHFFFAOYSA-N 0.000 description 2
- MRIXVKKOHPQOFK-UHFFFAOYSA-N 4-methoxysalicylic acid Chemical compound COC1=CC=C(C(O)=O)C(O)=C1 MRIXVKKOHPQOFK-UHFFFAOYSA-N 0.000 description 2
- YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 description 2
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- SGVYKUFIHHTIFL-UHFFFAOYSA-N Isobutylhexyl Natural products CCCCCCCC(C)C SGVYKUFIHHTIFL-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 229940031569 diisopropyl sebacate Drugs 0.000 description 2
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000010696 ester oil Substances 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000005661 hydrophobic surface Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- VKPSKYDESGTTFR-UHFFFAOYSA-N isododecane Natural products CC(C)(C)CC(C)CC(C)(C)C VKPSKYDESGTTFR-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- QUAMTGJKVDWJEQ-UHFFFAOYSA-N octabenzone Chemical compound OC1=CC(OCCCCCCCC)=CC=C1C(=O)C1=CC=CC=C1 QUAMTGJKVDWJEQ-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229960003921 octisalate Drugs 0.000 description 2
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 239000008385 outer phase Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 2
- 229960001173 oxybenzone Drugs 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 235000019871 vegetable fat Nutrition 0.000 description 2
- 230000007332 vesicle formation Effects 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- BITHHVVYSMSWAG-KTKRTIGZSA-N (11Z)-icos-11-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCC(O)=O BITHHVVYSMSWAG-KTKRTIGZSA-N 0.000 description 1
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 description 1
- VBURMNYQYXSQEL-VFAVKCLXSA-N (2R)-2-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2H-furan-5-one (Z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O VBURMNYQYXSQEL-VFAVKCLXSA-N 0.000 description 1
- ADHNUPOJJCKWRT-JLXBFWJWSA-N (2e,4e)-octadeca-2,4-dienoic acid Chemical compound CCCCCCCCCCCCC\C=C\C=C\C(O)=O ADHNUPOJJCKWRT-JLXBFWJWSA-N 0.000 description 1
- ZUUFLXSNVWQOJW-MBIXAETLSA-N (2e,4e,6e)-octadeca-2,4,6-trienoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C(O)=O ZUUFLXSNVWQOJW-MBIXAETLSA-N 0.000 description 1
- IRVNEGRHQKGRGD-WPXUHFOISA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;hexadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O IRVNEGRHQKGRGD-WPXUHFOISA-N 0.000 description 1
- PBTPTBMYJPCXRQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;hexadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCC(O)=O PBTPTBMYJPCXRQ-MGMRMFRLSA-N 0.000 description 1
- MHUOEHQATDLJFZ-WPXUHFOISA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;octadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O MHUOEHQATDLJFZ-WPXUHFOISA-N 0.000 description 1
- ATNNLHXCRAAGJS-QZQOTICOSA-N (e)-docos-2-enoic acid Chemical compound CCCCCCCCCCCCCCCCCCC\C=C\C(O)=O ATNNLHXCRAAGJS-QZQOTICOSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- NWGAAWUUGRXXSC-UHFFFAOYSA-N 1-(2-hydroxypropoxy)propan-2-yl 2-hydroxybenzoate Chemical compound CC(O)COCC(C)OC(=O)C1=CC=CC=C1O NWGAAWUUGRXXSC-UHFFFAOYSA-N 0.000 description 1
- UAFHRUBCOQPFFM-UHFFFAOYSA-N 1-(aminomethyl)cyclohexane-1-carboxylic acid Chemical compound NCC1(C(O)=O)CCCCC1 UAFHRUBCOQPFFM-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- DHGBAFGZLVRESL-UHFFFAOYSA-N 14-methylpentadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C DHGBAFGZLVRESL-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- MEZZCSHVIGVWFI-UHFFFAOYSA-N 2,2'-Dihydroxy-4-methoxybenzophenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1O MEZZCSHVIGVWFI-UHFFFAOYSA-N 0.000 description 1
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- RKJGFHYCZPZJPE-UHFFFAOYSA-N 2,2-bis(16-methylheptadecanoyloxymethyl)butyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(CC)(COC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C RKJGFHYCZPZJPE-UHFFFAOYSA-N 0.000 description 1
- JNAYPSWVMNJOPQ-UHFFFAOYSA-N 2,3-bis(16-methylheptadecanoyloxy)propyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C JNAYPSWVMNJOPQ-UHFFFAOYSA-N 0.000 description 1
- DGSZGZSCHSQXFV-UHFFFAOYSA-N 2,3-bis(2-ethylhexanoyloxy)propyl 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(OC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DGSZGZSCHSQXFV-UHFFFAOYSA-N 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- WHQOKFZWSDOTQP-UHFFFAOYSA-N 2,3-dihydroxypropyl 4-aminobenzoate Chemical compound NC1=CC=C(C(=O)OCC(O)CO)C=C1 WHQOKFZWSDOTQP-UHFFFAOYSA-N 0.000 description 1
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- ZXDDPOHVAMWLBH-UHFFFAOYSA-N 2,4-Dihydroxybenzophenone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=CC=C1 ZXDDPOHVAMWLBH-UHFFFAOYSA-N 0.000 description 1
- CECHHHFZXNTPMP-UHFFFAOYSA-N 2-(2,2-dimethylpropanoyloxy)ethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCCOC(=O)C(C)(C)C CECHHHFZXNTPMP-UHFFFAOYSA-N 0.000 description 1
- HSMMDRNFKHECNY-UHFFFAOYSA-N 2-(2,3-dihydroxypropyl)-2-ethylhexanoic acid;2,3-dimethoxy-3-phenylprop-2-enoic acid Chemical compound CCCCC(CC)(C(O)=O)CC(O)CO.COC(C(O)=O)=C(OC)C1=CC=CC=C1 HSMMDRNFKHECNY-UHFFFAOYSA-N 0.000 description 1
- ALBXRBNFWICCSC-UHFFFAOYSA-N 2-(5,5-dimethyl-1,1-diphenylhex-1-en-3-ylidene)propanedioic acid Chemical compound C=1C=CC=CC=1C(=CC(CC(C)(C)C)=C(C(O)=O)C(O)=O)C1=CC=CC=C1 ALBXRBNFWICCSC-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- KKDLMTFRMQVLMO-UHFFFAOYSA-N 2-heptylundecyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CCCCCCC)CCCCCCCCC KKDLMTFRMQVLMO-UHFFFAOYSA-N 0.000 description 1
- JVXJFNLEXLGQIO-UHFFFAOYSA-N 2-hexyldecyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CCCCCC)CCCCCCCC JVXJFNLEXLGQIO-UHFFFAOYSA-N 0.000 description 1
- OGJDIJKJFYOENF-UHFFFAOYSA-N 2-hexyldecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCC)CCCCCCCC OGJDIJKJFYOENF-UHFFFAOYSA-N 0.000 description 1
- JUIYTAQAHOONSH-UHFFFAOYSA-N 2-hydroxy-4-propan-2-yloxybenzoic acid Chemical compound CC(C)OC1=CC=C(C(O)=O)C(O)=C1 JUIYTAQAHOONSH-UHFFFAOYSA-N 0.000 description 1
- IXKMJGZLCSWMTD-UHFFFAOYSA-N 2-hydroxy-4-propoxybenzoic acid Chemical compound CCCOC1=CC=C(C(O)=O)C(O)=C1 IXKMJGZLCSWMTD-UHFFFAOYSA-N 0.000 description 1
- AAUQLHHARJUJEH-UHFFFAOYSA-N 2-hydroxy-5-methoxybenzoic acid Natural products COC1=CC=CC(O)=C1C(O)=O AAUQLHHARJUJEH-UHFFFAOYSA-N 0.000 description 1
- VHCJSVNQEBEVMO-UHFFFAOYSA-N 2-hydroxy-5-propoxybenzoic acid Chemical compound CCCOC1=CC=C(O)C(C(O)=O)=C1 VHCJSVNQEBEVMO-UHFFFAOYSA-N 0.000 description 1
- ORWUQAQITKSSRZ-UHFFFAOYSA-N 2-hydroxyethyl 4-[bis[2-(2-hydroxyethoxy)ethyl]amino]benzoate Chemical compound OCCOCCN(CCOCCO)C1=CC=C(C(=O)OCCO)C=C1 ORWUQAQITKSSRZ-UHFFFAOYSA-N 0.000 description 1
- CIHKVMHPDDJIIP-UHFFFAOYSA-N 2-methylperoxybenzoic acid Chemical compound COOC1=CC=CC=C1C(O)=O CIHKVMHPDDJIIP-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- DWYHDSLIWMUSOO-UHFFFAOYSA-N 2-phenyl-1h-benzimidazole Chemical class C1=CC=CC=C1C1=NC2=CC=CC=C2N1 DWYHDSLIWMUSOO-UHFFFAOYSA-N 0.000 description 1
- ZSNLEVJATWJBLU-UHFFFAOYSA-N 2-tert-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(C(C)(C)C)(OC)C(=O)C1=CC=CC=C1 ZSNLEVJATWJBLU-UHFFFAOYSA-N 0.000 description 1
- PKYUNJWBVAXPMG-UHFFFAOYSA-N 3-ethoxy-2-hydroxybenzoic acid Chemical compound CCOC1=CC=CC(C(O)=O)=C1O PKYUNJWBVAXPMG-UHFFFAOYSA-N 0.000 description 1
- ZQXRINMCMHCYBD-UHFFFAOYSA-N 4-(2-ethylhexoxy)-4-oxobutanoic acid Chemical compound CCCCC(CC)COC(=O)CCC(O)=O ZQXRINMCMHCYBD-UHFFFAOYSA-N 0.000 description 1
- JBRMEFWJFBHUKG-UHFFFAOYSA-N 4-[(diaminomethylideneamino)methyl]cyclohexane-1-carboxylic acid Chemical compound NC(N)=NCC1CCC(C(O)=O)CC1 JBRMEFWJFBHUKG-UHFFFAOYSA-N 0.000 description 1
- RNGFVIMNTYOBTK-UHFFFAOYSA-N 4-butoxy-2-hydroxybenzoic acid Chemical compound CCCCOC1=CC=C(C(O)=O)C(O)=C1 RNGFVIMNTYOBTK-UHFFFAOYSA-N 0.000 description 1
- DVZPQHRWOUXUPU-UHFFFAOYSA-N 4-ethoxy-2-hydroxybenzoic acid Chemical compound CCOC1=CC=C(C(O)=O)C(O)=C1 DVZPQHRWOUXUPU-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- ZZKFPIOJAOEMQL-UHFFFAOYSA-N 5-ethoxy-2-hydroxybenzoic acid Chemical compound CCOC1=CC=C(O)C(C(O)=O)=C1 ZZKFPIOJAOEMQL-UHFFFAOYSA-N 0.000 description 1
- MVJSIAIXMFGVSA-UHFFFAOYSA-N 6-(2-hexyldecoxy)-6-oxohexanoic acid Chemical compound CCCCCCCCC(CCCCCC)COC(=O)CCCCC(O)=O MVJSIAIXMFGVSA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- LITUBCVUXPBCGA-WMZHIEFXSA-N Ascorbyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O LITUBCVUXPBCGA-WMZHIEFXSA-N 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- UEQVLKWMHAYVLO-MGCOHNPYSA-N C1C[C@@H](CN)CC[C@@H]1C(=O)OC1=CC=C(O)C=C1C(O)=O Chemical compound C1C[C@@H](CN)CC[C@@H]1C(=O)OC1=CC=C(O)C=C1C(O)=O UEQVLKWMHAYVLO-MGCOHNPYSA-N 0.000 description 1
- AVWTXYWHGFHGQD-ZKCHVHJHSA-N CNC(=O)[C@H]1CC[C@H](CN)CC1 Chemical compound CNC(=O)[C@H]1CC[C@H](CN)CC1 AVWTXYWHGFHGQD-ZKCHVHJHSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- RDOFJDLLWVCMRU-UHFFFAOYSA-N Diisobutyl adipate Chemical compound CC(C)COC(=O)CCCCC(=O)OCC(C)C RDOFJDLLWVCMRU-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- KIENGQUGHPTFGC-JLAZNSOCSA-N L-ascorbic acid 6-phosphate Chemical compound OP(=O)(O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O KIENGQUGHPTFGC-JLAZNSOCSA-N 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- YQINWFJNFJEWHH-UCLHFMLVSA-N OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O YQINWFJNFJEWHH-UCLHFMLVSA-N 0.000 description 1
- GAKOHFNTEXOHTP-RXSVEWSESA-N OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.OP(O)(=O)OP(O)(=O)OP(O)(O)=O Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.OP(O)(=O)OP(O)(=O)OP(O)(O)=O GAKOHFNTEXOHTP-RXSVEWSESA-N 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004482 WACKER® Polymers 0.000 description 1
- XKMYWNHZAQUEPY-YZGJEOKZSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 12-hydroxyoctadecanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCC(O)CCCCCC)C1 XKMYWNHZAQUEPY-YZGJEOKZSA-N 0.000 description 1
- DRRMRHKHTQRWMB-UHFFFAOYSA-N [3-(2-ethylhexanoyloxy)-2,2-bis(2-ethylhexanoyloxymethyl)propyl] 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(COC(=O)C(CC)CCCC)(COC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DRRMRHKHTQRWMB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- UBNYRXMKIIGMKK-RMKNXTFCSA-N amiloxate Chemical compound COC1=CC=C(\C=C\C(=O)OCCC(C)C)C=C1 UBNYRXMKIIGMKK-RMKNXTFCSA-N 0.000 description 1
- 229960002709 amiloxate Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940072049 amyl acetate Drugs 0.000 description 1
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072065 ascorbic acid 2-sulfate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- XVAMCHGMPYWHNL-UHFFFAOYSA-N bemotrizinol Chemical compound OC1=CC(OCC(CC)CCCC)=CC=C1C1=NC(C=2C=CC(OC)=CC=2)=NC(C=2C(=CC(OCC(CC)CCCC)=CC=2)O)=N1 XVAMCHGMPYWHNL-UHFFFAOYSA-N 0.000 description 1
- 150000008316 benzisoxazoles Chemical class 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 229940111759 benzophenone-2 Drugs 0.000 description 1
- 229940079894 benzophenone-9 Drugs 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- HGKOWIQVWAQWDS-UHFFFAOYSA-N bis(16-methylheptadecyl) 2-hydroxybutanedioate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CC(O)C(=O)OCCCCCCCCCCCCCCCC(C)C HGKOWIQVWAQWDS-UHFFFAOYSA-N 0.000 description 1
- WXNRYSGJLQFHBR-UHFFFAOYSA-N bis(2,4-dihydroxyphenyl)methanone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=C(O)C=C1O WXNRYSGJLQFHBR-UHFFFAOYSA-N 0.000 description 1
- SODJJEXAWOSSON-UHFFFAOYSA-N bis(2-hydroxy-4-methoxyphenyl)methanone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=C(OC)C=C1O SODJJEXAWOSSON-UHFFFAOYSA-N 0.000 description 1
- YEAYGXLRPMKZBP-KQGICBIGSA-N bis(2-hydroxyethyl)azanium;(e)-3-(4-methoxyphenyl)prop-2-enoate Chemical compound OCCNCCO.COC1=CC=C(\C=C\C(O)=O)C=C1 YEAYGXLRPMKZBP-KQGICBIGSA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- VQWFNAGFNGABOH-UHFFFAOYSA-K chromium(iii) hydroxide Chemical compound [OH-].[OH-].[OH-].[Cr+3] VQWFNAGFNGABOH-UHFFFAOYSA-K 0.000 description 1
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 description 1
- 229910000152 cobalt phosphate Inorganic materials 0.000 description 1
- LFSBSHDDAGNCTM-UHFFFAOYSA-N cobalt(2+);oxygen(2-);titanium(4+) Chemical compound [O-2].[O-2].[O-2].[Ti+4].[Co+2] LFSBSHDDAGNCTM-UHFFFAOYSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical class C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- FDATWRLUYRHCJE-UHFFFAOYSA-N diethylamino hydroxybenzoyl hexyl benzoate Chemical compound CCCCCCOC(=O)C1=CC=CC=C1C(=O)C1=CC=C(N(CC)CC)C=C1O FDATWRLUYRHCJE-UHFFFAOYSA-N 0.000 description 1
- 229960001630 diethylamino hydroxybenzoyl hexyl benzoate Drugs 0.000 description 1
- 229940031769 diisobutyl adipate Drugs 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 229940079784 disodium stearoyl glutamate Drugs 0.000 description 1
- WODOUQLMOIMKAL-FJSYBICCSA-L disodium;(2s)-2-(octadecanoylamino)pentanedioate Chemical compound [Na+].[Na+].CCCCCCCCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CCC([O-])=O WODOUQLMOIMKAL-FJSYBICCSA-L 0.000 description 1
- QDCHWIWENYCPIL-UHFFFAOYSA-L disodium;4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC(S([O-])(=O)=O)=C(OC)C=C1O QDCHWIWENYCPIL-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- HUVYTMDMDZRHBN-UHFFFAOYSA-N drometrizole trisiloxane Chemical compound C[Si](C)(C)O[Si](C)(O[Si](C)(C)C)CC(C)CC1=CC(C)=CC(N2N=C3C=CC=CC3=N2)=C1O HUVYTMDMDZRHBN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 229940068998 egg yolk phospholipid Drugs 0.000 description 1
- 229940108623 eicosenoic acid Drugs 0.000 description 1
- BITHHVVYSMSWAG-UHFFFAOYSA-N eicosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCC(O)=O BITHHVVYSMSWAG-UHFFFAOYSA-N 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 1
- 229960000655 ensulizole Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- CBZHHQOZZQEZNJ-UHFFFAOYSA-N ethyl 4-[bis(2-hydroxypropyl)amino]benzoate Chemical compound CCOC(=O)C1=CC=C(N(CC(C)O)CC(C)O)C=C1 CBZHHQOZZQEZNJ-UHFFFAOYSA-N 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- GQXQIRNPJBUEGY-UHFFFAOYSA-N hexadecan-7-yl 2,2-dimethyloctanoate Chemical compound CCCCCCCCCC(CCCCCC)OC(=O)C(C)(C)CCCCCC GQXQIRNPJBUEGY-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000002462 imidazolines Chemical class 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- JCDAAXRCMMPNBO-UHFFFAOYSA-N iron(3+);oxygen(2-);titanium(4+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Ti+4].[Ti+4].[Fe+3].[Fe+3] JCDAAXRCMMPNBO-UHFFFAOYSA-N 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- SOXAGEOHPCXXIO-DVOMOZLQSA-N menthyl anthranilate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)C1=CC=CC=C1N SOXAGEOHPCXXIO-DVOMOZLQSA-N 0.000 description 1
- 229960002248 meradimate Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 229940114937 microcrystalline wax Drugs 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008239 natural water Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940083254 peripheral vasodilators imidazoline derivative Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920000575 polymersome Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- QXQOYJODXQCGON-UHFFFAOYSA-M potassium;2-methylperoxybenzoate Chemical compound [K+].COOC1=CC=CC=C1C([O-])=O QXQOYJODXQCGON-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- XATKDVHSLQMHSY-RMKNXTFCSA-N propan-2-yl (e)-3-(4-methoxyphenyl)prop-2-enoate Chemical compound COC1=CC=C(\C=C\C(=O)OC(C)C)C=C1 XATKDVHSLQMHSY-RMKNXTFCSA-N 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- NNNVXFKZMRGJPM-KHPPLWFESA-N sapienic acid Chemical compound CCCCCCCCC\C=C/CCCCC(O)=O NNNVXFKZMRGJPM-KHPPLWFESA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 229940078455 sodium lauroyl aspartate Drugs 0.000 description 1
- 229940045944 sodium lauroyl glutamate Drugs 0.000 description 1
- IWIUXJGIDSGWDN-UQKRIMTDSA-M sodium;(2s)-2-(dodecanoylamino)pentanedioate;hydron Chemical compound [Na+].CCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CCC(O)=O IWIUXJGIDSGWDN-UQKRIMTDSA-M 0.000 description 1
- IEXXLSKKBWIDAC-ZOWNYOTGSA-M sodium;(3s)-3-(dodecanoylamino)-4-hydroxy-4-oxobutanoate Chemical compound [Na+].CCCCCCCCCCCC(=O)N[C@H](C([O-])=O)CC(O)=O IEXXLSKKBWIDAC-ZOWNYOTGSA-M 0.000 description 1
- KJCLYACXIWMFCC-UHFFFAOYSA-M sodium;5-benzoyl-4-hydroxy-2-methoxybenzenesulfonate Chemical compound [Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 KJCLYACXIWMFCC-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 1
- 229960000368 sulisobenzone Drugs 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- IBYFOBGPNPINBU-UHFFFAOYSA-N tetradecenoic acid Natural products CCCCCCCCCCCC=CC(O)=O IBYFOBGPNPINBU-UHFFFAOYSA-N 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 238000012719 thermal polymerization Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- IBYFOBGPNPINBU-OUKQBFOZSA-N trans-2-tetradecenoic acid Chemical compound CCCCCCCCCCC\C=C\C(O)=O IBYFOBGPNPINBU-OUKQBFOZSA-N 0.000 description 1
- LKOVPWSSZFDYPG-WUKNDPDISA-N trans-octadec-2-enoic acid Chemical compound CCCCCCCCCCCCCCC\C=C\C(O)=O LKOVPWSSZFDYPG-WUKNDPDISA-N 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 229940118594 trimethylolpropane triisostearate Drugs 0.000 description 1
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 1
- UEVAMYPIMMOEFW-UHFFFAOYSA-N trolamine salicylate Chemical compound OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O UEVAMYPIMMOEFW-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/42—Colour properties
- A61K2800/43—Pigments; Dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/54—Polymers characterized by specific structures/properties
- A61K2800/542—Polymers characterized by specific structures/properties characterized by the charge
- A61K2800/5424—Polymers characterized by specific structures/properties characterized by the charge anionic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/60—Particulates further characterized by their structure or composition
- A61K2800/61—Surface treated
- A61K2800/612—By organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
Definitions
- the present invention can stably blend an ultraviolet absorber and a pigment in an emulsion containing a vesicle-forming amphipathic substance as an emulsifier.
- an ultraviolet absorber and a pigment in an emulsion containing a vesicle-forming amphipathic substance as an emulsifier.
- underwater oil-type emulsified cosmetics with improved cosmetic effects such as lack of sensation.
- Some amphipathic substances form spherical closures consisting of bilayer membranes (lamella liquid crystals) in the aqueous phase, and such bilayer membrane closures are called vesicles. Vesicles can retain water-soluble components inside the closed body, oil-based components can be retained inside the bilayer membrane, and can be expected to have effects such as improving the stability of the system, so they are the basis of cosmetics. It is used as an agent.
- Patent Document 1 an oil-in-water emulsified cosmetic containing a water-holding oil content in the internal phase is obtained by forming a vesicle with polyoxyethylene hydrogenated castor oil and adhering the vesicle to the surface of an oil droplet.
- the problem of blending many pigments in the oil phase has not been recognized, and it is unclear whether many pigments can be stably blended.
- an ultraviolet absorber other than ethylhexyl methoxycinnamate and an inorganic powder such as a pigment are added to the oil phase to obtain a high ultraviolet protection effect.
- an ultraviolet absorber other than ethylhexyl methoxycinnamate and an inorganic powder such as a pigment are added to the oil phase to obtain a high ultraviolet protection effect.
- an inorganic powder such as a pigment
- An object of the present invention is to provide an oil-in-water emulsified cosmetic that can stably blend an ultraviolet absorber other than ethylhexyl methoxycinnamate and a pigment in an oil phase and has excellent vibration stability. ..
- the present invention (A) Vesicle-forming amphipathic substance, Provided is an oil-in-water emulsified cosmetic containing (B) an oil containing an ultraviolet absorber other than ethylhexyl methoxycinnamate, and (C) an amino acid surface-treated pigment.
- the cosmetic according to the present invention has the above-mentioned structure, and is excellent in vibration stability even when ethylhexyl methoxycinnamate is not added to an emulsion containing a vesicle-forming amphipathic substance as an emulsifier, and skin. It is possible to improve cosmetic effects such as familiarity with the skin, uniformity of the coating film, and lack of thick coating feeling. Therefore, it is possible to realize a cosmetic that is more suitable for carrying.
- the emulsifying base according to the present invention has sufficient emulsifying power, it is also possible to add a water-soluble agent such as a salt-type whitening agent, which tends to have poor stability when added to the aqueous phase, which is usually the outer phase. It becomes.
- the cosmetic according to the present invention is characterized by containing (A) a vesicle-forming amphoteric substance, (B) an oil containing an ultraviolet absorber other than ethylhexyl methoxycinnamate, and (C) an amino acid surface-treated pigment. ..
- A a vesicle-forming amphoteric substance
- B an oil containing an ultraviolet absorber other than ethylhexyl methoxycinnamate
- C an amino acid surface-treated pigment.
- the (A) vesicle-forming amphipathic substance (hereinafter, may be simply referred to as “(A) component”) blended in the cosmetics according to the present invention is an amphipathic substance that forms vesicles. It has emulsifying power.
- the vesicle-forming amphipathic substance is not particularly limited, and examples thereof include silicone-based surfactants, block-type alkylene oxide derivatives, sugar fatty acid esters, polyoxyethylene hydrogenated castor oil derivatives, acyl amino acid metal salts, and phospholipids. Can be mentioned.
- the silicone-based surfactant is not particularly limited, and examples thereof include polyoxyalkylene-modified silicone. From the viewpoint of usability and vesicle formability, it is preferable to use the polyoxyalkylene-modified silicone represented by the following formula (1).
- R 1 is a side chain in the polysiloxane structure of the main chain and is a hydrogen or an alkyl group having 1 to 6 carbon atoms, and even if they are the same, they are independently different. You may. For example, when R 1 is all methyl groups, it has a dimethylpolysiloxane structure, and when it is a methyl group and a phenyl group, it has a methylphenylpolysiloxane structure.
- A is a place where a polyoxyalkylene group can be introduced in the polysiloxane structure of the main chain, and at least one of them is the formula:-(CH 2 ) a- (C 2 H 4 O) b- (C 3 H 6 ).
- R 2 is hydrogen or an alkyl group having 1 to 6 carbon atoms
- a is an integer of 1 to 6
- b is an integer of 0 to 50
- c is an integer of 0 to 50
- b + c is at least. 5 or more.
- the other A when a part of A is the above-mentioned polyoxyalkylene group, the other A may be hydrogen or an alkyl group having 1 to 6 carbon atoms.
- the silicone represented by the formula (1) is, for example, a polyoxyalkylene-modified silicone represented by ABA type when the two terminals A are polyoxyalkylene groups, while only the non-terminal A is. When it is a polyoxyalkylene group, it is a pendant type polyoxyalkylene modified silicone.
- the polyoxyalkylene group may be any of a polyoxyethylene group, a polyoxypropylene group, and a polyoxyethylene / polyoxypropylene group.
- M indicating the number of moles of the unsubstituted polysiloxane structure is an integer of 1 to 200
- n indicating the number of moles of the polyoxyalkylene substituted polysiloxane structure is an integer of 0 to 50.
- polyoxyalkylene-modified silicone examples include polyoxyethylene (polyoxyethylene), which is a pendant-type polyoxyalkylene-modified silicone in which the side chain methyl group of linear dimethylpolysiloxane is replaced with a polyoxyethylene (12 mol) group. It is preferable to use 12 mol) modified dimethylpolysiloxane, polyoxyethylene (8 mol) modified dimethylpolysiloxane, polyoxyethylene (20 mol) modified dimethylpolysiloxane, and ABA type polyoxyethylene. -Methylsiloxane-Polyoxyethylene block copolymer and the like can be mentioned.
- the molecular weight of ethylene oxide in the total molecular weight is preferably 20 to 60%.
- the polyoxyalkylene-modified silicone of the present invention preferably has an HLB of less than 10 in the HLB calculation according to the Griffin formula.
- PEG-12 dimethicone in which c is 0 and b is 12 in the above formula is particularly preferable. Further, it is more preferable that PEG-12 dimethicone has an HLB of less than 10.
- Block type alkylene oxide derivative As the block-type alkylene oxide derivative, a block-type alkylene oxide derivative represented by the following formula (2) or formula (3) can be used. Vesicles composed of block-type alkylene oxide derivatives are also called polymersomes.
- EO is an oxyethylene group
- AO is an oxyalkylene group having 3 to 4 carbon atoms
- these addition forms are block-like.
- Specific examples of the AO include an oxypropylene group, an oxybutylene group, an oxyisobutylene group, an oxytrimethylene group and an oxytetramethylene group.
- an oxypropylene group and an oxybutylene group are preferable, and an oxybutylene group is preferable. Is particularly preferable.
- e and g represent the average number of moles of oxyethylene groups added, and f represents the average number of moles of oxyalkylene groups added.
- e and g are preferably in the range of 1 ⁇ e + g ⁇ 70, more preferably in the range of 5 ⁇ e + g ⁇ 60, and f is preferably in the range of 1 ⁇ f ⁇ 70.
- the range of 5 ⁇ f ⁇ 55 is more preferable.
- the ratio of the oxyethylene group to the total of the oxyalkylene group having 3 to 4 carbon atoms and the oxyethylene group is 20 to 80% by mass from the viewpoint of vesicle formability and the like. It is preferably 30 to 70% by mass, more preferably 30 to 70% by mass.
- the molecular weight of the alkylene oxide derivative represented by the formula (2) is preferably 1000 to 5000 from the viewpoint of obtaining a sufficient amount of vesicles.
- R 3 and R 4 are hydrocarbon groups having 1 to 4 carbon atoms, and may be the same or different from each other.
- the hydrocarbon group having 1 to 4 carbon atoms include a methyl group, an ethyl group, an N-propyl group, an isopropyl group, an N-butyl group, a sec-butyl group, a tert-butyl group and the like, and among them, methyl.
- a group and an ethyl group are preferable.
- a vesicle may be formed by combining one or more block - type alkylene oxide derivatives having the same or different R3 and R4 .
- R3 and R4 may contain a derivative of a hydrogen atom as long as the effect of the present invention is not affected. ..
- the block-type alkylene oxide derivative of the present invention can be produced by a known method.
- a block-type alkylene oxide derivative is obtained by addition-polymerizing ethylene oxide and an alkylene oxide having 3 to 4 carbon atoms to a compound having a hydroxyl group and then subjecting an alkyl halide to an ether reaction in the presence of an alkaline catalyst. be able to.
- the block-type alkylene oxide derivative represented by the formula (2) is not particularly limited, and for example, POE (9) POP (2) dimethyl ether, POE (14) POP (7) dimethyl ether, POE (10) POP ( 10) Dimethyl ether, POE (6) POP (14) Dimethyl ether, POE (15) POP (5) Dimethyl ether, POE (25) POP (25) Dimethyl ether, POE (7) POP (12) Dimethyl ether, POE (22) POP ( 40) Dimethyl ether, POE (35) POP (40) Dimethyl ether, POE (50) POP (40) Dimethyl ether, POE (55) POP (30) Dimethyl ether, POE (30) POP (34) Dimethyl ether, POE (25) POP ( 30) Dimethyl ether, POE (27) POP (14) Dimethyl ether, POE (55) POP (28) Dimethyl ether, POE (36) POP (41) Dimethyl ether, POE (17) POP (4) Dimethyl ether, POE (9) PO
- POE, POP, and POB are abbreviations for polyoxyethylene, polyoxypropylene, and polyoxybutylene, respectively, and the numbers in parentheses after POE, POP, and POB represent the number of added moles of each.
- it may be abbreviated as follows.
- B is a residue obtained by removing a hydroxyl group from dimerdiol
- EO is an oxyethylene group.
- AO is an oxyalkylene group having 3 to 4 carbon atoms, and examples thereof include an oxypropylene group, an oxybutylene group, an oxyisobutylene group, an oxyt-butylene group, and among them, an oxypropylene group and an oxybutylene group.
- an oxybutylene group is more preferred.
- the additional forms of B, EO and AO are block-like from the viewpoint of vesicle formation.
- the addition order is preferably AO and EO in the order of AO and EO.
- s 1 and s 2 represent the average number of moles of oxyethylene groups added, and r 1 and r 2 represent the average number of moles of oxyalkylene groups added. From the viewpoint of vesicle stability, usability, etc., these are preferably in the range of 1 ⁇ s 1 + s 2 ⁇ 150 and 1 ⁇ r 1 + r 2 ⁇ 150, 5 ⁇ s 1 + s 2 ⁇ 120 and 2.
- the range of ⁇ r 1 + r 2 ⁇ 70 is more preferable, and the range of 10 ⁇ s 1 + s 2 ⁇ 100 and 2 ⁇ r 1 + r 2 ⁇ 50 is particularly preferable.
- the ratio of the oxyethylene group to the total of the oxyethylene group and the oxyalkylene group is preferably 10 to 99% by mass, more preferably 20 to 70% by mass from the viewpoint of vesicle formability.
- the molecular weight of the alkylene oxide derivative represented by the formula (3) is preferably 1000 to 6000 from the viewpoint of vesicle formability.
- R 3 and R 4 are hydrocarbon groups having 1 to 4 carbon atoms. Since the hydroxyl groups at the ends that cause stickiness can be etherified, R 3 and R 4 can improve the compatibility with the skin and provide a good feeling of use.
- the hydrocarbon group include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, a sec-butyl group, a tert-butyl group and a mixed group thereof, and among them, a methyl group and an ethyl group. Groups are preferred.
- R 3 and R 4 may be the same or different, and one or two or more block-type alkylene oxide derivatives having the same or different R 3 and R 4 may be combined to form a vesicle.
- B is a residue obtained by removing the hydroxyl group from the dimerdiol.
- the dimer diol is a diol obtained by reducing dimer acid.
- B is another diol other than the dimer diol, the vesicle may not be formed, or even if the vesicle can be formed, the stability may be insufficient.
- Fatty acid which is a raw material of dimer diol, is a dimer obtained by polymerizing, for example, an unsaturated fatty acid or a lower alcohol ester thereof, and specifically, an unsaturated fatty acid such as oleic acid, linoleic acid, or linoleic acid.
- the esters of these lower alcohols can be synthesized by a method of reacting by thermal polymerization such as the Deals-Alder reaction or another reaction method. Unreacted fatty acid may remain in the produced fatty acid as long as the effect of the present invention is not impaired.
- dimer acid an unsaturated fatty acid having 12 to 24 carbon atoms or a dimerized lower alcohol ester thereof is preferable.
- B is a dimerdiol residue having 24 to 48 carbon atoms.
- unsaturated fatty acids include myristoleic acid, palmitoleic acid, oleic acid, ellagic acid, baxenoic acid, gadrain acid, erucic acid, nervonic acid, linoleic acid, linoleic acid and lower grades having 1 to 3 carbon atoms thereof. Examples thereof include unsaturated fatty acids having 18 carbon atoms, and oleic acid or linoleic acid or a lower alcohol ester thereof is more preferable.
- dimer acid dimer acid obtained by hydrogenating the remaining unsaturated double bond after dimerization may be used.
- dimer diol those derived from animal fats and oils and those derived from vegetable fats and oils are commercially available, and both can be used in the present invention, but those derived from vegetable fats and oils are more preferable.
- dimer diols include Sovermol 908 (manufactured by Cognis Japan), PRIPOL (registered trademark) 2033 (manufactured by Unichema), and Pespol HP-1000 (manufactured by Toagosei).
- the block-type alkylene oxide derivative represented by the formula (3) is not particularly limited, and for example, POB (25) POE (34) dimethyl dimer diol ether, POB (25) POE (35) dimethyl dimer diol ether, and the like.
- Such a block-type alkylene oxide derivative can be produced by a known method.
- a block-type alkylene oxide derivative is obtained by addition-polymerizing ethylene oxide and an alkylene oxide having 3 to 4 carbon atoms to a compound having a hydroxyl group and then subjecting an alkyl halide to an ether reaction in the presence of an alkaline catalyst. be able to.
- sugar fatty acid ester examples include sucrose fatty acid ester, maltitol fatty acid ester, trehalose fatty acid ester and the like.
- the number of hydroxyl group substitutions with the fatty acid is not particularly limited, but monoesters, diesters and triesters are preferable, monoesters and diesters are more preferable, and monoesters are even more preferable.
- the constituent fatty acids in the sugar fatty acid ester are saturated or unsaturated fatty acids having 12 to 22 carbon atoms, and are preferably linear or branched.
- these fatty acids include lauric acid, myristic acid, palmitic acid, stearic acid, isostearic acid, araquinic acid, bechenic acid, tetradecenoic acid, hexadecenoic acid, octadecenoic acid, octadecadienoic acid, eicosenoic acid, and eikosatetraenoic acid.
- Examples thereof include docosenoic acid and octadecatrienoic acid, and among them, stearic acid is preferable. In the case of diesters, the two fatty acids may be different.
- Polyoxyethylene hydrogenated castor oil derivative As the polyoxyethylene cured castor oil derivative, it is preferable to use a compound represented by the following formula (4).
- L + M + N + X + Y + Z indicates the average number of moles of added ethylene oxide E, and 10 ⁇ E ⁇ 20. That is, as the polyoxyethylene hydrogenated castor oil derivative, a derivative having an average addition molar number E of ethylene oxide (EO) of 10 to 20 can be used. If the average number of moles of EO added is less than 10, the emulsified composition of the present invention cannot be obtained because vesicle particles do not spontaneously form in the aqueous phase.
- EO ethylene oxide
- the HLB value of the polyoxyethylene hydrogenated castor oil derivative contained in the oil-in-water emulsified cosmetic of the present invention is preferably 11 or less.
- acyl amino acid metal salt As the acyl amino acid metal salt, an acyl amino acid metal salt having 12 to 22 carbon atoms is preferable. Examples of such an acyl amino acid metal salt include N-lauroyl-L sodium glutamate, N-stearoyl-L glutamate sodium, di (N-lauroyl glutamate) sodium lysine and the like.
- phospholipids examples include egg yolk phospholipids, soybean phospholipids, hydrogenated additives thereof, sphingomyelin lipids such as sphingomyelin, and glycerophospholipids such as lecithin.
- one selected from the above-mentioned vesicle-forming amphipathic substances may be used alone or in combination of two or more.
- one or more selected from the polyoxyalkylene-modified silicone represented by the formula (1) and the polyoxyethylene cured castor oil derivative represented by the formula (4) as the component (A) of the present invention Is preferable, and it is more preferable to use one or more selected from the polyoxyalkylene-modified silicone represented by the above formula (1).
- the blending amount of the component (A) is not particularly limited as long as it can form a vesicle, but is, for example, 0.1 to 5.0% by mass, preferably 0.3 to 3.0% by mass with respect to the total amount of cosmetics. %, More preferably 0.8 to 2.0% by mass. If the blending amount is less than 0.1% by mass, sufficient emulsifying power may not be obtained, and if it exceeds 5.0% by mass, the feeling of use may be impaired, such as stickiness.
- the (B) oil component (hereinafter, may be simply referred to as “(B) component”) contained in the cosmetics according to the present invention refers to an oil component that essentially contains an ultraviolet absorber other than ethylhexyl methoxycinnamate.
- the cosmetic of the present invention has an embodiment of 1% by mass or less when ethylhexyl methoxycinnamate is blended, and ethylhexyl methoxycinnamate. Includes aspects that do not substantially contain.
- the ultraviolet absorber other than ethylhexyl methoxycinnamate is not particularly limited, but one usually blended in cosmetics can be used.
- benzoic acid derivatives such as para-aminobenzoic acid (PABA) ethyl, ethyl-dihydroxypropyl PABA, ethylhexyl-dimethyl PABA, glyceryl PABA, PEG-25-PABA, diethylaminohydroxybenzoyl hexyl benzoate; homosalate, ethylhexyl salicylate.
- PABA para-aminobenzoic acid
- salicylic acid derivatives such as octyl salicylate, dipropylene glycol salicylate, TEA salicylate; isopropyl methoxycinnamate, isoamyl methoxycinnamate, cinnoxate, DEA methoxycinnamate, diisopropyl methylsilicate, glyceryl-ethylhexanoate-dimethoxycinnamate, Dibenzoic acid derivatives such as di- (2-ethylhexyl) -4'-methoxybenzalmaronate; dibenzoylmethane derivatives such as 4-tert-butyl-4'-methoxydibenzoylmethane; ⁇ , ⁇ -diphenyl such as octocrylene.
- octyl salicylate dipropylene glycol salicylate, TEA salicylate
- isopropyl methoxycinnamate isoamyl methoxyc
- benzophenone derivatives such as benzophenone-1, benzophenone-2, benzophenone-3 or oxybenzone, benzophenone-4, benzophenone-5, benzophenone-6, benzophenone-8, benzophenone-9, benzophenone-12; 3-benzilidenshonow, Benzylidene sulphonic acid, phenyl benzimidazole sulfonic acid, phenyldibenzimidazole tetrasulfonic acid Phenylbenzimidazole derivatives such as disodium; bisethylhexyloxyphenol methoxyphenyltriazine, ethylhexyltriazone, diethylhexylbutamidotriazone, 2,4,6-tris (diisobutyl-4'-aminobenzalmaronate) -s- Triazine derivatives such as triazine, 2,4,6-tris [4- (2-ethy
- the ultraviolet absorber of the present invention indispensably contains at least one selected from a salicylic acid derivative and a ⁇ , ⁇ -diphenyl acrylate derivative. Furthermore, it is preferable that octocrylene, homosalate and octyl salicylate are essentially contained.
- the amount of the ultraviolet absorber to be blended in the cosmetic according to the present invention is 1 to 40% by mass, preferably 3 to 30% by mass, and more preferably 5 to 25% by mass with respect to the total amount of the cosmetic. be. If the blending amount of the UV absorber is less than 1% by mass, it is difficult to obtain a sufficient UV protection effect, and even if the blending amount exceeds 40% by mass, the UV protection effect cannot be expected to increase in proportion to the blending amount, and the stability is rather stable. It is not preferable because it deteriorates usability.
- the oil component (B) of the present invention may further contain one or more selected from hydrocarbon oils, ester oils and silicone oils.
- hydrocarbon oil examples include isododecane, isohexadecane, hydrogenated polydecene, isoparaffin, liquid paraffin, ozokerite, squalane, pristane, paraffin, ceresin, squalane, petrolatum, microcrystalline wax and the like.
- ester oil examples include isopropyl myristate, cetyl ethylcaproate, octyldodecyl myristate, isopropyl palmitate, butyl stearate, hexyl laurate, myristyl myristate, decyl oleate, hexyldecyl dimethyloctanoate, and cetyl lactate.
- Myristyl Lactate Lanoline acetate, Isocetyl stearate, Isocetyl isostearate, Cholesteryl 12-hydroxystearate, Ethylene glycol di-2-ethylcaproate, Dipentaerythritol fatty acid ester, N-alkyl glycol monoisostearate, Neopentyl dicaprate Glycol, diisostearyl malate, glycerin di-2-heptylundecanoate, trimethylolpropane tri-2-ethylcaproate, trimethylolpropane triisostearate, glycerin triisostearate, pentaerythrityl tetraethylhexanoate, triethylhexa Noin (glyceryl tri-2-ethylcaproate), cetyl 2-ethylhexanoate, 2-ethylhexyl palmitate, glycerin trim
- silicone oil examples include chain polysiloxane (eg, dimethylpolysiloxane, methylphenylpolysiloxane, diphenylpolysiloxane, etc.) and cyclic polysiloxane (eg, octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethyl, etc.).
- chain polysiloxane eg, dimethylpolysiloxane, methylphenylpolysiloxane, diphenylpolysiloxane, etc.
- cyclic polysiloxane eg, octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethyl, etc.
- Silicone resin forming a three-dimensional network structure, silicone rubber, various modified polysiloxanes (amino-modified polysiloxane, polyether-modified polysiloxane, alkyl-modified polysiloxane, fluorine-modified polysiloxane, etc.), acrylic Examples include silicones.
- the amount of the oil (B) to be blended is not particularly limited as long as it is an amount normally used for blending the pigment in the oil phase, and for example, it may be 1 to 40% by mass with respect to the total amount of the cosmetic. (B) If the blending amount of the oil exceeds 40% by mass, the stability and usability tend to decrease.
- the oil (B) of the present invention may contain at least an ultraviolet absorber other than ethylhexyl methoxycinnamate. Therefore, the cosmetic of the present invention includes an embodiment containing only an ultraviolet absorber as an oil component.
- the low molecular weight oil is added to the total amount of the oil excluding the ultraviolet absorber.
- the proportion is preferably 50% or less in terms of mass ratio. Since it is not necessary to add the small molecule oil as the oil (B) of the present invention, the range of the ratio of the small molecule oil to the total amount of the oil excluding the ultraviolet absorber is 0 to 50%.
- the small molecule oil content refers to an oil content having a volatilization rate at 25 ° C. and a weight change rate of 30% or more per hour.
- the volatilization rate refers to the value of the rate of change in weight per hour measured under the condition of 25 ° C. by placing a filter paper on a glass petri dish, dropping about 0.2 g of a sample, and using a gravimetric method.
- Specific examples of the small molecule oil include isododecane, low-viscosity volatile silicone (low-viscosity dimethicone) having an average degree of polymerization of less than 650, and the like.
- Examples of commercially available small molecule oil products include Creasil ID CG (manufactured by Shima Trading Co., Ltd.) and KF-96L-1.5CS (manufactured by Shin-Etsu Chemical Co., Ltd.).
- the volatilization rate of Creasil ID CG is 90% or more, and the volatilization rate of KF-96L-1.5CS is about 50%.
- the (C) amino acid surface-treated pigment (hereinafter, may be simply referred to as “(C) component”) blended in the cosmetics according to the present invention is an inorganic whose surface is hydrophobized with a treatment agent containing an amino acid.
- a treatment agent containing an amino acid refers to pigments.
- Specific examples include iron oxide (Bengala), iron titanate, ⁇ -iron oxide, iron yellow oxide, ocher, black iron oxide, carbon black, lower-order titanium oxide, mango violet, cobalt violet, chromium oxide, and chromium hydroxide. , Cobalt titanate, ultramarine, dark blue, etc.
- the pigment of the present invention it is preferable to use pigment grade iron oxide such as yellow iron oxide, red iron oxide and black iron oxide, pigment grade titanium oxide and the like.
- the pigment grade means a pigment having an average particle size of 100 nm to 1 ⁇ m.
- the amino acid used for the hydrophobic surface treatment of the pigment of the present invention is preferably an amino acid acylated with a saturated fatty acid or a salt thereof.
- the "amino acid acylated with a saturated fatty acid or a salt thereof” is a compound or a salt thereof in which an acyl group, preferably a saturated fatty acid having 12 to 22 carbon atoms, is condensed with an amino group of an amino acid.
- the “amino acid” is preferably glutamic acid or aspartic acid.
- Examples of the "acyl group” include a stearoyl group and a lauroyl group.
- the “salt” can be selected from alkali metal salts such as sodium and potassium, alkaline earth metal salts and the like, but sodium salts are preferable.
- Specific examples of the acylated amino acid include disodium stearoyl glutamate, sodium lauroyl glutamate, and sodium lauroyl aspartate.
- Examples of the amino acid used for the hydrophobic surface treatment of the pigment of the present invention include N-acylglutamic acid, N-acylaspartic acid, N-acyllysine and the like.
- the pigment (C) used in the cosmetic of the present invention is preferably surface-treated with a treatment agent containing an amino acid selected from acylated glutamic acid and acylated aspartic acid.
- amino acid hydrophobized pigment grade iron oxide examples include NHS-Yellow LL-100P (manufactured by Miyoshi Kasei Kogyo Co., Ltd.), ASI-Yellow LL-100P (manufactured by Daito Kasei Kogyo Co., Ltd.), which are yellow iron oxide.
- LL-100P manufactured by Daito Kasei Kogyo Co., Ltd.
- NHS-Black BL-100P manufactured by Miyoshi Kasei Kogyo Co., Ltd.
- ASI-Black BL-100P manufactured by Daito Kasei Kogyo Co., Ltd.
- ASL-Black BL-100P which are black iron oxides.
- the blending amount of the component (C) is not particularly limited as long as a desired color is obtained, but is usually 1% by mass or more, for example, 1 to 30% by mass, preferably 1 to 20% by mass with respect to the total amount of cosmetics. If the blending amount is less than 1% by mass, sufficient color cannot be obtained, and if it exceeds 30% by mass, the stability tends to deteriorate.
- the cosmetic according to the present invention is a powder type composition in oil in water in which (C) a pigment is dispersed in oil droplets as an internal phase.
- the oil phase is preferably 1 to 50% by mass with respect to the total amount of the cosmetics.
- an aqueous component (hereinafter, may be simply referred to as "(D) component") may be blended.
- the (D) aqueous component of the present invention refers to a component whose main composition is a polyhydric alcohol such as water, ethanol (ethyl alcohol), dipropylene glycol, 1,3-butylene glycol, and glycerin.
- the (D) aqueous component it is preferable to use one or more selected from monohydric alcohols and divalent alcohols as the (D) aqueous component.
- the monohydric alcohol is not particularly limited as long as it is usually used for cosmetics, but examples thereof include ethyl alcohol, normal propyl alcohol, isopropyl alcohol and the like, and among them, ethyl alcohol is preferable.
- the divalent alcohol is not particularly limited as long as it is usually used for cosmetics, but examples thereof include 1,3-butylene glycol, dipropylene glycol and the like, and dipropylene glycol is preferable.
- the blending amount thereof is 1 to 15% by mass with respect to the total amount of the cosmetic, and when the dihydric alcohol is used alone, the blending amount thereof.
- the amount is 1 to 20% by mass with respect to the total amount of cosmetics.
- the total blending amount is 1 to 45% by mass, preferably 1 to 35% by mass, based on the total amount of the cosmetics. More preferably, it is preferable to blend with the concentration of the monohydric alcohol and the divalent alcohol satisfying the following formula (5) as the upper limit.
- the aqueous component (D) if the blending amount of the monohydric alcohol alone, the blending amount of the dihydric alcohol alone, and the total blending amount of the monohydric alcohol and the divalent alcohol is less than 1% by mass, the vesicle is not generated or the structure is formed. It may be disturbed and emulsification may be weakened. Further, when the blending amount of the monohydric alcohol alone exceeds 15% by mass or when the blending amount of the dihydric alcohol alone exceeds 20% by mass, the blending ratio of the monohydric alcohol and the dihydric alcohol is further in the above formula (5).
- the vesicle film becomes too flexible or the vesicles are transferred to the micelles, and the effect of improving stabilization is obtained. It may not be possible.
- an ionic surfactant (hereinafter, also simply referred to as “(E) component”) may be further blended.
- a vesicle-forming amphipathic substance is used as the emulsifier of the present invention, the stability of the vesicle can be further improved by adding an ionic surfactant to the aqueous phase.
- the (E) ionic surfactant to be blended in the cosmetic according to the present invention may be any as long as it is usually used in cosmetics, and is other than the component (A) and exhibits ionicity. Refers to things.
- an anionic surfactant as the (E) ionic surfactant to be blended in the cosmetic according to the present invention.
- sulfonate-type anionic surfactants are preferable.
- the sulfonate-type anionic surfactant include sulfosuccinic acid diester salt, alkylallyl sulfonate, alkyl ether sulfonate, sulfosuccinic acid ester salt, acylmethyl taurine salt, acyl taurine salt, potassium cetyl phosphate, and potassium cocoyl glutamate. And so on. Among them, it is preferable to select and use from acylmethyltaurine salt, potassium cetylphosphate and potassium cocoylglutamate, and it is more preferable to use N-acylmethyltaurine salt.
- N-acylmethyl taurine salts represented by the following formula (6) the N-stearoyl-N-methyl taurine salt is preferable.
- the blending amount of the component (E) is preferably 0.01 to 1% by mass, more preferably 0.01 to 0.1% by mass, and 0.01 to 0. It is more preferably 06% by mass. If the blending amount is less than 0.01% by mass, the effect of improving the stabilization of the vesicle may not be sufficiently obtained, and if it exceeds 1% by mass, the vesicle may be solubilized. Further, the mixing amount ratio of the component (A) and the ionic surfactant (E) is 1: 0 in terms of mass ratio. It is preferably 01 to 1: 0.06.
- a whitening agent is added to sunscreen cosmetics, but it is generally known that when a salt-type whitening agent is added to the aqueous phase, which is the outer phase, the stability tends to deteriorate. Since the cosmetic according to the present invention has sufficient emulsifying power, it has an effect of excellent vibration stability even when a salt-type whitening agent is added to the aqueous phase.
- the (F) whitening agent (hereinafter, may be simply referred to as "(F) component”) blended in the cosmetic according to the present invention is not particularly limited as long as it is normally blended in the cosmetic.
- Specific examples include L-ascorbic acid and its derivatives, tranexamic acid and its derivatives, alkoxysalicylic acid and its derivatives, glycyrrhizic acid and its derivatives, nicotinic acid and its derivatives, and the like.
- one kind or a combination of two or more kinds of the above-mentioned agents may be blended.
- L-ascorbic acid monoalkyl esters such as L-ascorbic acid monostearate, L-ascorbic acid monopalmitate, and L-ascorbic acid monoolate; L-ascorbic acid monophosphate ester, L.
- L-L-ascorbic acid monoesters such as ascorbic acid-2-sulfate ester
- L-ascorbic acid dialkyl esters such as L-ascorbic acid distearate, L-ascorbic acid dipalmitate, L-ascorbic acid dioleate
- L-ascorbic acid tri L-ascorbic acid trialkyl esters such as stearate, L-ascorbic acid tripalmitate, L-ascorbic acid triolate
- L-ascorbic acid triesters such as L-ascorbic acid triphosphate
- L-ascorbic acid 2 -L-ascorbic acid glucosides such as glucoside can be mentioned.
- L-ascorbic acid, L-ascorbic acid phosphate ester, L-ascorbic acid-2-sulfate ester, L-ascorbic acid 2-glucoside and salts thereof are preferably used.
- tranexamic acid Derivatives of tranexamic acid include dimers of tranexamic acid (eg, trans-4- (trans-aminomethylcyclohexanecarbonyl) aminomethylcyclohexanecarboxylic acid, etc.), esters of tranexamic acid and hydroquinone (eg, 4).
- tranexamic acid and a salt thereof are preferably used.
- the derivative of alkoxysalicylic acid is one in which the hydrogen atom at any of the 3-position, 4-position or 5-position of salicylic acid is substituted with an alkoxy group, and the alkoxy group as the substituent is preferably a methoxy group, an ethoxy group, or the like. It is any one of a propoxy group, an isopropoxy group, a butoxy group and an isobutoxy group, and more preferably a methoxy group or an ethoxy group.
- compound names include 3-methoxysalicylic acid, 3-ethoxysalicylic acid, 4-methoxysalicylic acid, 4-ethoxysalicylic acid, 4-propoxysalicylic acid, 4-isopropoxysalicylic acid, 4-butoxysalicylic acid, and 5-methoxysalicylic acid. , 5-ethoxysalicylic acid, 5-propoxysalicylic acid and the like.
- methoxysalicylic acid and a salt thereof are preferably used.
- Examples of the derivative of glycyrrhizic acid include salts of glycyrrhizic acid and esters of glycyrrhizic acid and higher alcohols.
- glycyrrhizic acid and salts thereof are preferably used.
- the salt of the above-mentioned drug is not particularly limited, and examples thereof include alkali metal salts such as sodium salt, potassium salt and calcium salt, alkaline earth metal salts, ammonium salts, amino acid salts and the like.
- nicotinic acid and its derivatives examples include nicotinic acid, benzyl nicotinate, nicotinic acid amide, and dl- ⁇ -tocopherol nicotinate. Nicotinamide is preferably used in the present invention.
- the blending amount of the whitening agent is 0.05 to 10% by mass, preferably 0.1 to 7% by mass, and more preferably 0.5 to 5% by mass with respect to the total amount of the cosmetic. If the blending amount is less than 0.05% by mass, it is difficult to obtain a sufficient medicinal effect, and if it exceeds 10% by mass, the stability and usability tend to deteriorate.
- the whitening agent (F) of the present invention may be dissolved or dispersed in the aqueous phase together with other aqueous components, or may be contained in the vesicle by being dissolved or dispersed in the aqueous phase in the process of forming the vesicle. You may.
- the cosmetic according to the present invention may contain one or more dispersants.
- the dispersant include sorbitan sesquiisostearate, isostearic acid, palmitic acid, polyhydroxystearic acid and the like.
- sorbitan sesquiisostearate and isostearic acid are exemplified as particularly suitable ones, and one or both of them may be blended.
- the dispersant is a selective compounding ingredient in the cosmetic of the present invention, it is not always necessary to blend it, but when it is blended, the effect of the blending is recognized and the blending amount is large. It is preferable to mix the mixture to the extent that no adverse effects such as excessive deterioration of usability are observed.
- the suitable blending amount of the dispersant in the cosmetic according to the present invention is preferably about 0.01 to 1% by mass with respect to the total amount of the cosmetic.
- the water to be blended in the cosmetic according to the present invention is selected as necessary, such as ion-exchanged water, purified water, tap water, and natural water.
- the blending amount is the remaining amount (mass% with respect to the total amount of cosmetics) with respect to the sum of the essential ingredient according to the present invention and other optional blending ingredients. Generally, about 30 to 70% by mass is preferable with respect to the total amount of cosmetics.
- the oil-in-water emulsified cosmetic according to the present invention includes, in addition to the above-mentioned ingredients, any other additive ingredients usually used for external skin preparations such as cosmetics and pharmaceuticals, as long as the purpose and effect of the present invention are not impaired.
- any other additive ingredients usually used for external skin preparations such as cosmetics and pharmaceuticals, as long as the purpose and effect of the present invention are not impaired.
- Powder components, fragrances and the like can be appropriately blended as needed.
- the present invention is not limited to these examples.
- the oil-in-water emulsified cosmetic according to one aspect of the present invention is characterized in that it is emulsified by a vesicle formed by the component (A).
- vesicle refers to a spherical closure having a bilayer membrane (lamellar liquid crystal) structure formed from an amphipathic block copolymer, with a water-soluble component inside the closure and an oily component inside the bilayer membrane. Each component can be retained and contributes to emulsification.
- Vesicle-forming vesicles are formed in the aqueous phase by an amphoteric substance, and then emulsified with the oil phase in the presence of the vesicles, so that the vesicles adhere to the surface of the oil droplets. It has a structure and oil droplets are stably dispersed in the aqueous phase. In the present specification, this emulsification method is referred to as "vesicle emulsification".
- the vesicle can be formed by a conventional method. For example, by mixing and stirring an aqueous component and a vesicle-forming amphipathic substance, a vesicle composed of a vesicle-forming amphipathic substance is formed in the aqueous phase.
- the water-soluble component usually used in cosmetics may be added to the water-based component in an amount within a range that does not impair the stability of the vesicle.
- the average particle size of the vesicle is not particularly limited, but is usually about 30 nm to 150 nm.
- the vesicle according to the present invention can be produced by a conventional method as a form in which a water-soluble component is contained inside the vesicle, or as a form in which an oil-based component is retained inside the bilayer film of the vesicle.
- the vesicle according to the present invention may be produced as a vesicle containing the agent by dissolving or dispersing a water-soluble agent such as a whitening agent in the aqueous phase.
- an oil-soluble component such as a fragrance is added and mixed, so that the oil-soluble component is mixed with the bimolecular film of the vesicle. It may be manufactured as a vesicle held inside.
- the vesicle according to the present invention is a vesicle water dispersion liquid obtained by sufficiently mixing a vesicle-forming amphoteric substance with an aqueous component and then dropping the mixture into an aqueous phase containing other water-soluble components with stirring.
- the mixed state of the vesicle-forming amphipathic substance and the aqueous component may be achieved by confirming that the mixed solution is transparent and in a one-phase state, for example, by mixing at room temperature to 90 ° C. for 1 to 30 minutes. can do.
- vesicle particles having an average particle size of 30 to 150 nm measured by a dynamic light scattering method can be obtained.
- the stirring device used for stirring is not particularly limited, and for example, a homomixer, a disper, or the like can be used.
- the vesicle particles formed in the aqueous phase can be molded into a sufficiently fine particle size by applying a strong share with the above-mentioned homomixer or the like, and uniformly dispersed in the aqueous phase.
- the degree of strong share is not particularly limited, but is usually about 5 minutes under the condition of 4000 to 12000 rpm by a homomixer.
- oil-in-water emulsified cosmetics emulsified with vesicles which is one aspect of the present invention
- (E) an ionic surfactant when (E) an ionic surfactant is further blended, vesicle particles are formed in the aqueous phase, and the vesicle-containing aqueous phase is used. It is preferable to add an oily component after adding an ionic surfactant to emulsify.
- the oil-in-water emulsified cosmetics emulsified with the vesicle which is one aspect of the present invention, can be produced by a conventional method.
- a vesicle forming step of mixing an aqueous component necessary for vesicle forming and a vesicle-forming amphipathic substance to form a vesicle, and in some cases, an ionic surfactant is added to the vesicle aqueous dispersion obtained by the above step.
- a step of adding and an emulsification step of emulsifying an oily component separately mixed and dissolved in the aqueous phase solution obtained in the above step while applying stirring and shearing force is provided with a step of adding and an emulsification step of emulsifying an oily component separately mixed and dissolved in the aqueous phase solution obtained in the above step while applying stirring and shearing force.
- the aqueous component necessary for vesicle formation and the vesicle-forming amphoteric substance are dissolved in advance, and the solution is mixed with the remaining water and other water-soluble components to form a vesicle in the aqueous phase.
- the vesicle dispersion may be obtained, or the vesicles are dispersed in the aqueous phase by mixing and stirring the vesicle-forming amphoteric substance in the aqueous phase containing the aqueous component and water and other water-soluble components.
- a vesicle dispersion may be obtained.
- the polyoxyalkylene-modified silicone represented by the formula (1) is used as the component (A), and monovalent alcohol and divalent alcohol are used as the component (D).
- Nanodisc emulsification can be realized by using an aqueous component selected from alcohol and further using an anionic surfactant as the component (E).
- a vesicle using a polyoxyalkylene-modified silicone (component (A)) represented by the formula (1) and an aqueous component (component (D)) selected from monovalent alcohol and divalent alcohol is used as the component (A)
- component (D) monovalent alcohol and divalent alcohol.
- the anionic surfactant (component (E)) and the oily component are added to the vesicle-containing aqueous solution and dispersed by stirring. It can be an emulsified cosmetic having a three-phase structure of -nanodisc phase-oil phase. In the present specification, this emulsification by nanodisc is referred to as "nanodisc emulsification".
- the cosmetic obtained by nanodisc emulsification has a very strong emulsifying power and has excellent vibration stability.
- nanodisc is a flat plate-shaped lamellar liquid crystal closure whose precursor is a vesicle (lamellar liquid crystal spherical closure) formed by an amphipathic substance, and contains a water-soluble component inside the closure. However, it refers to a substance having an amphipathic group at the edge portion. Nanodiscs exist as precursor vesicles in oil-free compositions, and the vesicles undergo structural changes (hereinafter also referred to as "transfers”) to nanodisks by adding oil and emulsifying.
- the nanodisc formed in the present invention is a vesicle aqueous dispersion obtained by mixing an aqueous component selected from a monohydric alcohol and a divalent alcohol with a polyoxyalkylene-modified silicone to form a vesicle, and an anionic surfactant. And oil are added and dispersed while applying a strong stirring force. Nanodiscs exist in a state of being adsorbed on the oil-water interface in an emulsified state, and contribute to emulsification stability.
- the nanodisc in the present invention is also referred to as "silicone nanodisk" because the amphipathic substance forming the vesicle is a silicone-based surfactant.
- the major axis of the nanodisk is 20 nm to 1000 nm.
- the water-soluble component is not included in the vesicle.
- the vesicle retains the oil-soluble component in the bilayer membrane of the vesicle by adding and mixing an oil-soluble component such as a fragrance in the step of mixing the vesicle-forming amphipathic substance and the aqueous component. It may be manufactured as a vesicle.
- the surface of the spherical vesicles formed by the surfactant is entirely covered with hydrophilic groups, but since nanodiscs have lipophilic groups at the edges, it is difficult to generate nanodisks in water.
- the surfactant polyether-modified silicone, etc.
- the surfactant is hydrophilized by the solvent effect, and as a result, the transfer from spherical vesicles to nanodisks is promoted.
- polyoxyalkylene-modified silicone such as PEG-12 dimethicone
- trihydric alcohols such as glycerin and polyhydric alcohols such as sorbitol make surfactants lipophilic and inhibit transfer to nanodisks. Tend to do. Therefore, when a trihydric or higher alcohol is blended, it is desirable that the total amount of the monohydric and divalent alcohols is larger than the total amount of the trivalent or higher polyhydric alcohols.
- the anionic surfactant may be any one that is usually used for cosmetics, and refers to a surfactant having an anionic hydrophilic group such as a carboxylic acid, a sulfonic acid, or one having a phosphoric acid structure. Above all, it is preferable to use an anionic surfactant having a Krafft temperature higher than room temperature. When the Krafft temperature of the anionic surfactant is lower than room temperature, the silicone-based surfactant and the anionic surfactant are likely to mix and interact with each other, which tends to prevent the transfer from the vesicle to the nanodisc. be.
- the anionic surfactant for nanodisc emulsification it is preferable to select and use from acylmethyltaurine salt, potassium cetylphosphate and potassium cocoylglutamate, and it is more preferable to use N-acylmethyltaurine salt. Further, among the N-acylmethyl taurine salts represented by the following formula (6), the N-stearoyl-N-methyl taurine salt is preferable.
- the oil-in-water emulsified cosmetic by nanodisc emulsification which is another aspect of the present invention, can be produced by a conventional method.
- polyoxyalkylene-modified silicone is dropped onto an aqueous component to form vesicle particles to obtain a vesicle aqueous dispersion, and an oily component separately mixed and dissolved with an anionic surfactant in this vesicle aqueous dispersion.
- the vesicles are transferred to the nanodisks, forming a three-phase structure of aqueous phase-nanodisk phase-oil phase.
- Oil droplets consisting of oily components are emulsified and dispersed in the aqueous phase, and nanodisks are localized on the surface of the oil droplet particles, so that the emulsification stability is excellent and the feeling of use (freshness, non-stickiness) is also improved.
- the stirring device used for stirring is not particularly limited, and for example, a homomixer, a disper, or the like can be used.
- the method for producing an oil-in-water emulsified cosmetic by nanodisc emulsification of the present invention includes a vesicle forming step of mixing an aqueous component and a polyoxyalkylene-modified silicone to form a vesicle, and a vesicle obtained in the vesicle forming step.
- the aqueous component and the polyoxyalkylene-modified silicone are previously dissolved, and the solution is mixed with the remaining water and other water-soluble components to obtain a vesicle dispersion liquid in which the vesicles are dispersed in the aqueous phase. It may be obtained, or a vesicle dispersion liquid in which vesicles are dispersed in the aqueous phase may be obtained by mixing and stirring a polyoxyalkylene-modified silicone in an aqueous phase containing an aqueous component and water and other water-soluble components.
- the cosmetic according to the present invention has a fresh feeling of use peculiar to an oil-in-water emulsion, and has the effect of improving the familiarity with the skin, the uniformity of the coating film, and the lack of thick coating.
- the vesicle-containing emulsion or nanodisc-containing emulsion according to the present invention can be blended with an amount of oil that cannot be blended with a normal solubilized product, yet a refreshing feeling of use can be obtained.
- the cosmetic according to the present invention is suitably used in various dosage forms such as creamy, milky liquid, and liquid.
- a product form it can be a makeup base containing a pigment, a foundation, an eyeliner, an eyeshadow, or other makeup cosmetics.
- the present invention will be described in more detail with reference to examples below, but the present invention is not limited thereto.
- the blending amount is shown in mass% with respect to the system in which the component is blended.
- Vibration stability The evaluation of placing 30 ml of the prepared sample in a resin tube, applying vibration for 30 minutes under the condition of 10 Hz or higher, and visually observing the emulsified separation of the sample and the agglomeration state of the powder after standing is based on the following criteria. I went there. A: No emulsification destruction or powder agglomeration is observed. B: Emulsification destruction and powder agglomeration are rarely seen. C: Emulsification destruction and powder agglomeration are observed. D: Emulsification destruction and powder agglomeration are severely observed.
- Examples 1 to 6, Comparative Examples 1 to 3 An oil-in-water emulsified cosmetic having the composition shown in the table on the next page was prepared. Specifically, ethanol and an amphoteric substance (polyoxyalkylene-modified silicone, polyoxyethylene hydrogenated castor oil) forming a vesicle are mixed and stirred, and then other aqueous components are mixed to obtain an aqueous phase solution. Examples 1 to 6 are obtained by adding an ionic surfactant to the aqueous phase solution and then mixing the oil phase solution obtained by separately mixing the oily component and the powder component with the aqueous phase solution while stirring. And the oil-in-water emulsified cosmetics of Comparative Examples 1 to 3 were obtained. The prepared sample was evaluated for vibration stability and cosmetic effect according to the above-mentioned evaluation method. The results are shown in the table.
- the cosmetics of Examples 1 to 4, Example 6 and Comparative Examples 1 to 3 using polyoxyalkylene-modified silicone as the component (A) are nanodisc emulsified, and polyoxyethylene as the component (A).
- the cosmetic of Example 5 using the cured castor oil derivative is based on vesicle emulsification.
- the cosmetics of Examples 1 to 6 containing the pigment surface-treated with the treatment agent containing amino acids were all excellent in vibration stability and cosmetic effect.
- the cosmetics of Comparative Examples 1 to 3 containing a pigment surface-treated with a treatment agent containing no amino acid sufficient vibration stability could not be obtained even if the type of the ultraviolet absorber to be blended was changed.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
(A)ベシクル形成性両親媒性物質、
(B)メトキシケイヒ酸エチルヘキシル以外の紫外線吸収剤を含む油分、および
(C)アミノ酸表面処理顔料
を含む、水中油型乳化化粧料を提供する。
本発明に係る化粧料に配合される(A)ベシクル形成性両親媒性物質(以下、単に「(A)成分」と称する場合がある)は、ベシクルを形成する両親媒性物質であって、乳化力のあるものをいう。ベシクル形成性両親媒性物質としては、特に限定されないが、例えば、シリコーン系界面活性剤、ブロック型アルキレンオキシド誘導体、糖脂肪酸エステル、ポリオキシエチレン硬化ヒマシ油誘導体、アシルアミノ酸金属塩、リン脂質等が挙げられる。
シリコーン系界面活性剤としては、特に限定されないが、例えば、ポリオキシアルキレン変性シリコーン等が挙げられる。使用感触、ベシクルの形成性の観点から、下記の式(1)に示されるポリオキシアルキレン変性シリコーンを用いることが好ましい。
本発明のポリオキシアルキレン変性シリコーンとしては、グリフィンの式によるHLB計算においてHLBが10未満であることが好ましい。
ブロック型アルキレンオキシド誘導体としては、下記の式(2)または式(3)で示されるブロック型アルキレンオキシド誘導体を用いることができる。ブロック型アルキレンオキシド誘導体から構成されるベシクルは、ポリマーソームとも呼ばれる。
前記式(2)で示されるアルキレンオキシド誘導体の分子量は、十分量のベシクルを得る観点から、1000~5000であることが好ましい。
前記式(3)で表されるアルキレンオキシド誘導体の分子量は、ベシクルの形成性の観点から、1000~6000であることが好ましい。
糖脂肪酸エステルとしては、例えば、ショ糖脂肪酸エステル、マルチトール脂肪酸エステル、トレハロース脂肪酸エステル等が挙げられる。
ポリオキシエチレン硬化ヒマシ油誘導体としては、下記式(4)で示される化合物を用いることが好ましい。
すなわち、ポリオキシエチレン硬化ヒマシ油誘導体は、エチレンオキシド(EO)の平均付加モル数Eが10~20である誘導体が使用可能である。EOの平均付加モル数が10より小さいと、水相中で自発的にベシクル粒子を形成しないため、本発明の乳化組成物を得ることができない。また、20より大きいと、ベシクル粒子を形成しながら十分な乳化ができない上、ぬめりを感じる、肌へのなじみに劣る等、使用性の点で満足するものが得られない。また、本発明の水中油型乳化化粧料に配合されるポリオキシエチレン硬化ヒマシ油誘導体のHLB値は、11以下であることが好適である。
アシルアミノ酸金属塩としては、炭素原子数12~22のアシルアミノ酸金属塩が好ましい。このようなアシルアミノ酸金属塩としては、例えば、N-ラウロイル-Lグルタミン酸ナトリウム、N-ステアロイル-Lグルタミン酸ナトリウム、ジ(N-ラウロイルグルタミル)リシンナトリウム等が挙げられる。
リン脂質としては、例えば、卵黄リン脂質、大豆リン脂質、およびこれらの水素添加物、スフィンゴミエリン等のスフィンゴリン脂質、レシチン等のグリセロリン脂質等が挙げられる。
本発明に係る化粧料に配合される(B)油分(以下、単に「(B)成分」と称する場合がある)は、メトキシケイヒ酸エチルヘキシル以外の紫外線吸収剤を必須に含む油分を指す。メトキシケイヒ酸エチルヘキシル以外の紫外線吸収剤により紫外線防御能を得る観点から、本発明の化粧料は、メトキシケイヒ酸エチルヘキシルが配合される場合には1質量%以下である態様、および、メトキシケイヒ酸エチルヘキシルを実質的に含まない態様を包含する。
本発明の(B)油分としては少なくともメトキシケイヒ酸エチルヘキシル以外の紫外線吸収剤を含めばよい。よって、本発明の化粧料は、油分として紫外線吸収剤のみを含む態様を包含する。
本発明に係る化粧料に配合される(C)アミノ酸表面処理顔料(以下、単に「(C)成分」と称する場合がある)は、表面がアミノ酸を含む処理剤により疎水化処理されている無機顔料を指す。具体例としては、酸化鉄(ベンガラ)、チタン酸鉄、γ-酸化鉄、黄酸化鉄、黄土、黒酸化鉄、カーボンブラック、低次酸化チタン、マンゴバイオレット、コバルトバイオレット、酸化クロム、水酸化クロム、チタン酸コバルト、群青、紺青等が挙げられる。なかでも、本発明の顔料としては、黄酸化鉄、赤酸化鉄、黒酸化鉄等の顔料級酸化鉄、顔料級酸化チタン等を用いることが好ましい。ここで、顔料級とは平均粒子径が100nm~1μmのものをいう。
本発明の顔料の疎水化表面処理に用いるアミノ酸としては、N-アシルグルタミン酸、N-アシルアスパラギン酸、N-アシルリジン等が挙げられる。
本発明の化粧料に用いる(C)顔料としては、アシル化グルタミン酸およびアシル化アスパラギン酸から選択されるアミノ酸を含む処理剤により表面処理されているのが好ましい。
2価アルコールとしては、化粧料に通常用いられるものであれば特に限定されないが、1,3-ブチレングリコール、ジプロピレングリコール等が挙げられ、なかでもジプロピレングリコールが好ましい。
水相中1価アルコール濃度(%)/15+水相中2価アルコール濃度(質量%)/20≦1 (5)
本発明に係る化粧料に配合される(E)イオン性界面活性剤としては、通常化粧料に用いられるものであればよく、前記(A)成分以外のものであって、かつイオン性を示すものを指す。
また、(A)成分と(E)イオン性界面活性剤との配合量比が質量比にして1:0 .01~1:0.06であることが好ましい。
本発明の一態様である水中油型乳化化粧料は、前記(A)成分により形成されるベシクルにより乳化されていることを特徴とする。ここで「ベシクル」とは、両親媒性ブロックコポリマーから形成される二分子膜(ラメラ液晶)構造を有する球状閉鎖体を指し、閉鎖体内部には水溶性成分を、二分子膜内部には油性成分をそれぞれ保持可能であるとともに、乳化に寄与する。ベシクル形成性両親媒性物質により水相中にベシクルを形成させ、その後ベシクル存在下で油相と乳化することにより、ベシクルが油滴表面に付着した、水相-ベシクル相-油相の三相構造となり、水相中に油滴が安定して分散する。本明細書においては、この乳化方法を「ベシクル乳化」という。
本発明の他の態様の水中油型乳化化粧料では、前記(A)成分として前記式(1)で表されるポリオキシアルキレン変性シリコーンを用い、前記(D)成分として1価アルコールおよび2価アルコールから選択される水性成分を用い、さらに前記(E)成分としてアニオン性界面活性剤を用いることにより、ナノディスク乳化を実現することができる。
具体的には、前記式(1)で表されるポリオキシアルキレン変性シリコーン((A)成分)と1価アルコールおよび2価アルコールから選択される水性成分((D)成分)とを用いてベシクルを形成させ、アニオン性界面活性剤((E)成分)と油性成分をベシクル含有水溶液に添加して攪拌分散することによって、ベシクルから構造変化して生じるナノディスクが油水界面に付着した、水相-ナノディスク相-油相の三相構造を有する乳化化粧料とすることができる。本明細書においては、このナノディスクによる乳化を「ナノディスク乳化」という。ナノディスク乳化により得た化粧料は乳化力が非常に強く、優れた振動安定性を有する。
したがって、本発明のナノディスク乳化による水中油型乳化化粧料の製造方法は、水性成分とポリオキシアルキレン変性シリコーンとを混合してベシクルを形成するベシクル形成工程と、ベシクル形成工程で得られたベシクル分散液に、アニオン性界面活性剤を添加して混合液を得る工程と、前記工程によって得られた混合液に別途混合溶解した油性成分を攪拌およびせん断力を加えながら乳化させる乳化工程と、を備える。
調製した試料30mlを樹脂チューブに入れ、30分間、10Hz以上の条件で振動を与え、静置後の試料の乳化分離および粉末の凝集状態を目視により観察した評価は以下の基準に基づいて行った。
A:乳化破壊や粉末の凝集が見られない。
B:乳化破壊や粉末の凝集があまり見られない。
C:乳化破壊や粉末の凝集が見られる。
D:乳化破壊や粉末の凝集が激しく見られる。
10名の専門パネルによる実使用試験によって評価した。具体的には、調製した試料を皮膚に塗布した際の化粧効果(肌へのなじみ、塗膜の均一性、厚塗りのなさ)について各々以下の基準に従って評価を行った。
A:10人中7人以上が良いと感じる。
B:10人中4~6人が良いと感じる。
C:10人中3人以下が良いと感じる。
次頁の表に掲げた組成を有する水中油型乳化化粧料を調製した。具体的には、エタノールとベシクルを形成する両親媒性物質(ポリオキシアルキレン変性シリコーン、ポリオキシエチレン硬化ヒマシ油)とを混合攪拌した後、他の水性成分を混合して水相溶液を得、前記水相溶液にイオン性界面活性剤を添加した後、油性成分および粉末成分を別途混合して得た油相溶液を、前記水相溶液に攪拌しながら混合することによって、実施例1~6および比較例1~3の水中油型乳化化粧料を得た。調製した試料について、前記した評価方法に従って振動安定性および化粧効果を評価した。結果は表中に示す。
*2:シリコーン・アミノ酸(トリメチルメトキシシラン、ステアロイルグルタミン酸2Na、水酸化Al)処理赤色酸化鉄
*3:シリコーン・アミノ酸(トリメチルメトキシシラン、ステアロイルグルタミン酸2Na、水酸化Al)処理黄色酸化鉄
*4:シリコーン・アミノ酸(トリメチルメトキシシラン、ステアロイルグルタミン酸2Na、水酸化Al)処理黒色酸化鉄
*5:アミノ酸・エステル(セバシン酸イソステアリル、ステアロイルグルタミン酸2Na、水酸化Al)処理酸化チタン
*6:アミノ酸・エステル(セバシン酸イソステアリル、ステアロイルグルタミン酸2Na、水酸化Al)処理赤色酸化鉄
*7:アミノ酸・エステル(セバシン酸イソステアリル、ステアロイルグルタミン酸2Na、水酸化Al)処理黄色酸化鉄
*8:アミノ酸・エステル(セバシン酸イソステアリル、ステアロイルグルタミン酸2Na、水酸化Al)処理黒色酸化鉄
*9:アミノ酸(リシン、ラウロイルグルタミン酸Na、塩化Mg)処理酸化チタン
*10:アミノ酸(リシン、ラウロイルグルタミン酸Na、塩化Mg)処理赤色酸化鉄
*11:アミノ酸(リシン、ラウロイルグルタミン酸Na、塩化Mg)処理黄色酸化鉄
*12:アミノ酸(リシン、ラウロイルグルタミン酸Na、塩化Mg)処理黒色酸化鉄
*13:テトラメチルテトラハイドロジェンシクロテトラシロキサン処理酸化チタン
*14:テトラメチルテトラハイドロジェンシクロテトラシロキサン処理黄色酸化鉄
*15:テトラメチルテトラハイドロジェンシクロテトラシロキサン処理赤色酸化鉄
*16:テトラメチルテトラハイドロジェンシクロテトラシロキサン処理黒色酸化鉄
表に示されるように、アミノ酸を含む処理剤により表面処理した顔料を含む実施例1~6の化粧料はいずれも、振動安定性および化粧効果が優れていた。
一方、アミノ酸を含まない処理剤により表面処理した顔料を含む比較例1~3の化粧料は、配合する紫外線吸収剤の種類を変えても十分な振動安定性は得られなかった。
以下に、本発明の水中油型乳化化粧料の処方例を挙げる。本発明はこれらの処方例によって何ら限定されるものではなく、特許請求の範囲によって特定されるものであることはいうまでもない。なお、配合量はすべて製品全量に対する質量%で表す。
成分名称 配合量(質量%)
水 残余
EDTA-3Na 0.05
グリセリン 2
1,3-ブチレングリコール 8
フェノキシエタノール 0.5
(ジメチルアクリルアミド/アクリロイルジメチルタウリンNa)クロスポ
リマー 0.5
ステアロキシヒドロキシプロピルメチルセルロース 0.1
キサンタンガム 0.1
ステアロイルメチルタウリンNa 0.01
エタノール 5
PEG-12ジメチコン 1.5
セバシン酸ジイソプロピル 8
アミノ酸・エステル(セバシン酸イソステアリル、ステアロイルグルタミン
酸2Na、水酸化Al)処理酸化チタン 5
アミノ酸・エステル(セバシン酸イソステアリル、ステアロイルグルタミン
酸2Na、水酸化Al)処理黄色酸化鉄 1
アミノ酸・エステル(セバシン酸イソステアリル、ステアロイルグルタミン
酸2Na、水酸化Al)処理赤色酸化鉄 4
アミノ酸・エステル(セバシン酸イソステアリル、ステアロイルグルタミン
酸2Na、水酸化Al)処理黒色酸化鉄 0.1
サリチル酸エチルヘキシル 5
オクトクリレン 5
ホモサレート 5
セスキイソステアリン酸ソルビタン 0.5
イソステアリン酸 0.5
シリカ・シリコーン処理酸化亜鉛 12
成分名称 配合量(質量%)
水 残余
EDTA-3Na 0.05
グリセリン 2
1,3-ブチレングリコール 8
フェノキシエタノール 0.5
(ジメチルアクリルアミド/アクリロイルジメチルタウリンNa)クロスポ
リマー 0.5
ステアロキシヒドロキシプロピルメチルセルロース 0.1
キサンタンガム 0.1
ステアロイルメチルタウリンNa 0.01
エタノール 5
PEG-12ジメチコン 1.5
セバシン酸ジイソプロピル 8
アミノ酸・エステル(セバシン酸イソステアリル、ステアロイルグルタミン
酸2Na、水酸化Al)処理酸化チタン 5
アミノ酸・エステル(セバシン酸イソステアリル、ステアロイルグルタミン
酸2Na、水酸化Al)処理黄色酸化鉄 1
アミノ酸・エステル(セバシン酸イソステアリル、ステアロイルグルタミン
酸2Na、水酸化Al)処理赤色酸化鉄 4
アミノ酸・エステル(セバシン酸イソステアリル、ステアロイルグルタミン
酸2Na、水酸化Al)処理黒色酸化鉄 0.1
サリチル酸エチルヘキシル 5
オクトクリレン 5
ホモサレート 5
t-ブチルメトキシジベンゾイルメタン 2
セスキイソステアリン酸ソルビタン 0.5
イソステアリン酸 0.5
Claims (5)
- (A)ベシクル形成性両親媒性物質、
(B)メトキシケイヒ酸エチルヘキシル以外の紫外線吸収剤を含む油分、および
(C)アミノ酸表面処理顔料
を含む、水中油型乳化化粧料。 - 前記紫外線吸収剤が、サリチル酸誘導体およびβ,β-ジフェニルアクリレート誘導体から選択される1種以上を含む、請求項1に記載の水中油型乳化化粧料。
- メトキシケイヒ酸エチルヘキシルを実質的に含まない、請求項1または2に記載の水中油型乳化化粧料。
- [規則91に基づく訂正 08.10.2021]
前記(A)成分が、ポリオキシアルキレン変性シリコーンである場合に、
さらに、(D)1価アルコールおよび2価アルコールから選択される水性成分と、
(E)イオン性界面活性剤とを含み、
前記(D)水性成分が、1価アルコール単独の場合には化粧料全量に対して1~15質量%であり、2価アルコール単独の場合には化粧料全量に対して1~20質量%であり、1価アルコールと2価アルコールとの組み合わせである場合にはその合計量が化粧料全量に対して1~45質量%であり、
前記(E)イオン性界面活性剤がアニオン性界面活性剤である、請求項1から3のいずれか一項に記載の水中油型乳化化粧料。 - さらに、(F)美白剤を含む、請求項1から4のいずれか一項に記載の水中油型乳化化粧料。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022571037A JPWO2022137638A1 (ja) | 2020-12-25 | 2021-08-16 | |
CN202180079220.6A CN116761579A (zh) | 2020-12-25 | 2021-08-16 | 水包油型乳化化妆品 |
US18/038,892 US20240016726A1 (en) | 2020-12-25 | 2021-08-16 | Oil-in-water emulsion cosmetic |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JPPCT/JP2020/048754 | 2020-12-25 | ||
JP2020048754 | 2020-12-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022137638A1 true WO2022137638A1 (ja) | 2022-06-30 |
Family
ID=82158902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/029917 WO2022137638A1 (ja) | 2020-12-25 | 2021-08-16 | 水中油型乳化化粧料 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20240016726A1 (ja) |
JP (1) | JPWO2022137638A1 (ja) |
CN (1) | CN116761579A (ja) |
WO (1) | WO2022137638A1 (ja) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0867609A (ja) * | 1994-08-29 | 1996-03-12 | Shiseido Co Ltd | 処理粉体およびそれを含有した化粧料 |
JP2006056851A (ja) * | 2004-08-23 | 2006-03-02 | Shu Uemura:Kk | 化粧料 |
JP2007269720A (ja) * | 2006-03-31 | 2007-10-18 | Kose Corp | 顔料とリポソームを含む化粧料 |
JP2014088374A (ja) * | 2012-10-02 | 2014-05-15 | Kose Corp | 顔料とベシクルを含む化粧料 |
JP2014114274A (ja) * | 2012-11-14 | 2014-06-26 | Kao Corp | 水中油型乳化組成物 |
JP2019064960A (ja) * | 2017-09-29 | 2019-04-25 | 株式会社 資生堂 | 水中油型乳化化粧料 |
JP2019131498A (ja) * | 2018-01-30 | 2019-08-08 | 学校法人神奈川大学 | メイクアップ化粧料 |
-
2021
- 2021-08-16 US US18/038,892 patent/US20240016726A1/en active Pending
- 2021-08-16 WO PCT/JP2021/029917 patent/WO2022137638A1/ja active Application Filing
- 2021-08-16 JP JP2022571037A patent/JPWO2022137638A1/ja active Pending
- 2021-08-16 CN CN202180079220.6A patent/CN116761579A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0867609A (ja) * | 1994-08-29 | 1996-03-12 | Shiseido Co Ltd | 処理粉体およびそれを含有した化粧料 |
JP2006056851A (ja) * | 2004-08-23 | 2006-03-02 | Shu Uemura:Kk | 化粧料 |
JP2007269720A (ja) * | 2006-03-31 | 2007-10-18 | Kose Corp | 顔料とリポソームを含む化粧料 |
JP2014088374A (ja) * | 2012-10-02 | 2014-05-15 | Kose Corp | 顔料とベシクルを含む化粧料 |
JP2014114274A (ja) * | 2012-11-14 | 2014-06-26 | Kao Corp | 水中油型乳化組成物 |
JP2019064960A (ja) * | 2017-09-29 | 2019-04-25 | 株式会社 資生堂 | 水中油型乳化化粧料 |
JP2019131498A (ja) * | 2018-01-30 | 2019-08-08 | 学校法人神奈川大学 | メイクアップ化粧料 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2022137638A1 (ja) | 2022-06-30 |
US20240016726A1 (en) | 2024-01-18 |
CN116761579A (zh) | 2023-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4825931B2 (ja) | 水中油型化粧料 | |
US11529293B2 (en) | Oil-in-water emulsion cosmetic | |
US11077048B2 (en) | Oil-in-water emulsion cosmetic | |
JP6757713B2 (ja) | 水中油型乳化組成物 | |
US9861561B2 (en) | Aqueous composition | |
JP2024107425A (ja) | 化粧料 | |
JP2019178069A (ja) | O/w/o型乳化化粧料 | |
JP2011207789A (ja) | O/w/o型乳化化粧料 | |
CN116710042A (zh) | 水包油型防晒化妆品 | |
WO2022137638A1 (ja) | 水中油型乳化化粧料 | |
JP5957384B2 (ja) | W/o乳化化粧料 | |
JP7370820B2 (ja) | 水中油型組成物 | |
WO2022137637A1 (ja) | 水中油型乳化化粧料 | |
WO2022264841A1 (ja) | 水中油型乳化化粧料 | |
WO2024034394A1 (ja) | 水中油型乳化化粧料組成物 | |
WO2023032834A1 (ja) | 水中油型乳化化粧料 | |
WO2023032832A1 (ja) | 水中油型乳化化粧料 | |
WO2021221149A1 (ja) | 水中油型乳化組成物 | |
JP2022092287A (ja) | 水中油型乳化化粧料 | |
JP2021080195A (ja) | 油中水型乳化化粧料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21909798 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022571037 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18038892 Country of ref document: US Ref document number: 202180079220.6 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21909798 Country of ref document: EP Kind code of ref document: A1 |